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Abstract 
The past decade has witnessed a paradigm shift in the initial treatment of multiple myeloma with the 
introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved 
outcomes. High-dose therapy and autologous stem cell transplantation remains an important therapeutic 
option for patients with multiple myeloma eligible for the procedure. Before the advent of the novel 
agents, patients underwent stem cell collection prior to significant alkylating agent exposure, given its 
potential deleterious effect on stem cell collection. With increasing use of the novel agents in the upfront 
setting, several reports have emerged raising concerns about their impact on the ability to collect stem 
cells. An expert panel of the International Myeloma Working Group (IMWG) was convened to examine the 
implications of these therapies on stem collection in patients with myeloma and to develop 
recommendations for addressing these issues. Here we summarize the currently available data and present 
our perspective on the problem and potential options to overcome this problem. Specifically, we 
recommend early mobilization of stem cells, preferably within the first 4 cycles of initial therapy, in patients 
treated with novel agents and encourage participation in clinical trials evaluating novel approaches to stem 
cell mobilization.  
 
High-dose therapy and autologous stem cell transplantation for multiple myeloma 
High-dose therapy and autologous stem cell transplantation (ASCT) remains an integral component of the 
myeloma treatment algorithm for patients considered eligible for the procedure. The majority of the 
randomized clinical trials have demonstrated a superior progression-free survival among patients 
undergoing ASCT compared with those treated with only conventional therapies and ASCT was associated 
with superior overall survival in 3 of those.1–7 Subsequent randomized trials have further defined the role of 
ASCT by demonstrating equivalent overall survival for delayed transplantation compared with upfront 
ASCT, albeit with some compromise in the quality-of-life parameters.8 Introduction of novel agents such as 
thalidomide, lenalidomide, and bortezomib have resulted in a paradigm change in the therapy of 
myeloma.9–14 The high response rates with these agents, hitherto seen only in the context of high-dose 
therapy, have once again raised questions regarding the utility of ASCT in the setting of myeloma. Given the 
lack of long-term follow-up of patients treated with these new agents, the durability of these responses as 
well as their potential long-term adverse effects remain unknown and ASCT continues to be an important 
part of myeloma therapy.  
Despite the increased use of the newer drugs for the initial treatment of myeloma, there is a continuous 
increase in the number of ASCTs reported to the Center for International Blood and Marrow Transplant 
Research (CIBMTR), highlighting their continued important role. Currently, the novel agents appear best 
suited to be used as first-line therapy, enhancing the quality of responses prior to proceeding to ASCT and 
diminishing early mortality from the disease, or in selected patients as primary therapy, moving ASCT to a 
second-line position or as adjuncts to transplant conditioning regimens or as maintenance therapy in 
patients undergoing ASCT.15–23 Furthermore, in a randomized trial evaluating single versus double ASCT a 
survival advantage with tandem ASCT was demonstrated in an unplanned subset analysis for those patients 
not obtaining at least a very good partial response after the first ASCT. This observation has increased the 
number of ASCTs being performed for patients not achieving very good partial response after the first 
ASCT.24 In addition, ASCT can also be used as part of second-line therapy after relapse, especially among 
patients who achieved a durable response after the first ASCT.6,23 
The traditional approach to patients with newly diagnosed myeloma, considered to be candidates for ASCT, 
has been to provide initial therapy with 4 to 6 cycles of a non–alkylator-containing regimen followed by 
collection of stem cells and high-dose therapy. The initial therapy for the disease allows time to obtain 
necessary insurance approvals as well as control disease-related symptoms, simultaneously controlling 
toxicity by limiting the number of cycles. In addition, adequate disease control provides an opportunity to 
reverse disease-related complications where feasible, and generally improve the functional status of the 
patient, allowing for a safer transplantation. Until the advent of the novel agents, the initial therapy 
regimens commonly used were vincristine, doxorubicin, and dexamethasone (VAD) or single-agent 
dexamethasone, both of which shared the advantage of having little impact stem cell mobilization and 
collection. Previous studies had shown that alkylating agents can potentially affect the stem cell pool and 
thus interfere with the ability to collect adequate numbers of stem cells.25–28 
The number of CD34+ cells collected for ASCT is dependent on a number of factors, most importantly the 
number of intended transplantations. The cell collection target usually depends on patient age, upfront 
versus delayed ASCT, patient preference, patient performance status, and presence of comorbidities, 
among others. Traditionally, the target for CD34 cell collection for a single ASCT has been 4 to 6 × 106 
CD34+/kg, with studies showing a deleterious impact on engraftment characteristics once the number falls 
below 2 × 106 CD34+/kg.29,30 Use of more CD34 cells has not been consistently associated with any 
significant benefit in the parameters studied. Patient age is an important factor from several perspectives. 
Clearly there is decreasing use of stem cell transplantation (SCT) with increasing patient age, although 
selected patients with good performance status may undergo transplantation into their mid-70s. The target 
for stem cell collection is usually based on single transplantation in the United States, because Medicare 
reimburses only single SCT for myeloma. Finally, there is a clear impact of age on the ability to collect stem 
cells, with decreasing yield with advancing age.31 In the majority of patients undergoing an ASCT for 
myeloma, stem cells are collected from the peripheral blood following mobilization using growth factor 
administration with or with out preceding chemotherapy. A minority of patients undergo ASCT with stem 
cells collected through a bone marrow harvest. Use of cyclophosphamide or other chemotherapy regimens 
for myelosuppression to achieve rebound CD34+ cell spillover into the blood with enhanced effects of 
myeloid growth factors during the recovery phase of peripheral blood counts allows for a more rapid stem 
cell collection and higher numbers of collected CD34+ cells compared with myeloid growth factor alone.32–35 
Institutions differ in their standard approach for collecting stem cells, with pros and cons to either 
approach. Use of cyclophosphamide, although allowing better stem cell collection and less likelihood of a 
collection failure (less than the 2 × 106 CD34+/kg), prolongs the collection process while awaiting count 
recovery and increases the risk of febrile neutropenia and other infectious complications.  
One of the recent advances in the field of stem cell mobilization strategies has been the introduction of 
AMD3100 (plerixafor), a receptor chemokine receptor 4 (CXCR4) inhibitor. Previous studies have 
highlighted the role of CXCR4 in the stem cell mobilization induced by granulocyte colony-stimulating factor 
(G-CSF) and cyclophosphamide. Lévesque et al showed that mobilization of stem cells by G-CSF coincides in 
vivo with the cleavage of the N-terminus of the chemokine receptor CXCR4 on the stem cells in the BM, 
leading to loss of chemotaxis in response to the CXCR4 ligand, the chemokine stromal cell–derived factor-1 
(SDF-1/CXCL12).36 In addition, accumulation of serine proteases led to cleavage and inactivation of SDF-1. 
Originally developed as an anti-HIV drug, the ability of this drug to enhance peripheral mobilization of 
CD34+ cells was subsequently recognized. AMD3100, a reversible inhibitor of the binding of stromal cell–
derived factor-1α (SDF-1α, also known as CXCL12) to its cognate CXCR4, has been shown to increase the 
number of circulating CD34+ cells in healthy volunteers when administered alone or with G-CSF prior to 
treatment.37–39 Stem cells express CXCR4 and are known to migrate to the bone marrow through a 
chemoattractant effect of SDF-1α that is produced locally by bone marrow stromal cells. Once in the 
marrow, it is also believed that stem cell CXCR4 can act to help “anchor” these cells to stromal cell surface 
SDF-1α. AMD3100-induced leukocytosis and elevations in circulating hematopoietic progenitor cell levels 
are thought to result from a disruption of the CXCR4/CXCL12 interaction and cell adhesion effects, resulting 
in the appearance of both mature and pluripotent cells in the systemic circulation. AMD3100 has been 
shown to exert an additive effect on the number of circulating hematopoietic stem and progenitor cells 
when administered with G-CSF. AMD3100-3102 was a multicenter randomized, double-blind, placebo-
controlled comparative trial designed to examine the ability of 240 μg/kg AMD3100 plus G-CSF versus 
placebo plus G-CSF to mobilize CD34+ stem cells in patients with multiple myeloma (MM), who had not 
previously failed stem cell collections and had not received previous stem cell transplant. The primary end 
point, the percentage of patients who achieved 6 × 106 or more CD34+ cells/kg in 2 or fewer apheresis days, 
was met in 106 (72%) of 128 patients in the AMD plus G-CSF group and 53 (34%) of 154 patients in the 
placebo plus G-CSF group, (P < .001). Fifty-four percent of study patients reached target after 1 day of 
apheresis in the AMD + G-CSF group compared with 17.3% in the placebo plus G-CSF group. After 4 days of 
apheresis, these numbers were 86.8% and 56%, respectively.40 
 
Thalidomide-, lenalidomide-, or bortezomib-based regimens as initial therapy for multiple myeloma 
Introduction of thalidomide represented the first major therapeutic advance in myeloma in several 
decades. After the initial trials in relapsed myeloma, several randomized phase 3 trials of thalidomide and 
dexamethasone in patients with previously untreated myeloma were performed.15,18,41,42 Thalidomide 
combinations were associated with superior response rates and improved response duration with no 
definite impact on the overall survival compared with dexamethasone alone or VAD. This was followed by 
introduction of the thalidomide analog, lenalidomide, that in phase 2 trials resulted in very high response 
rates as well as deeper responses than were seen with previous approaches.11,43 Subsequent phase 3 trials 
of lenalidomide and dexamethasone demonstrated its superiority compared with dexamethasone alone as 
well as its ability to spare high doses of steroids and simultaneously improve survival.12,19 More recent 
clinical trials have examined the efficacy and tolerability of lenalidomide combined with cyclophosphamide 
(CTX), bortezomib, and clarithromycin, as well as other combinations.44–46 Another major advance in the 
field had been the introduction of the proteasome inhibitor bortezomib, which along with dexamethasone 
or in combination with conventional chemotherapy agents is increasingly being used in the setting of newly 
diagnosed disease with high efficacy. Phase 3 trials of bortezomib in combination with dexamethasone with 
or without doxorubicin has shown excellent tolerability and improved response rates and progression-free 
survival compared with traditional VAD in the setting of initial therapy prior to SCT.17,20,47 Both lenalidomide 
and bortezomib have been combined with cyclophosphamide in the setting of transplantation-eligible 
patients in phase 2 studies with excellent response rates.48,49 Recently reported phase 2 trials have 
examined the efficacy of combining bortezomib with lenalidomide or thalidomide with or without 
cyclophosphamide in the setting of newly diagnosed MM.50–53 These combinations have led to very high 
complete and very good partial response rates and will undoubtedly become integral components of the 
initial treatment choices in the future. This in turn has led to renewed interest in the potential impact of 
initial therapy on the ability to collect adequate numbers of stem cells for one or more transplantations.  
 
Impact of thalidomide, lenalidomide, and bortezomib on peripheral blood stem cell collection 
A large volume of data, albeit limited to single institution reports and less detailed data from phase 3 trials, 
has appeared in the past few years evaluating the effect of these new drugs on the stem cell collection 
process (Table 1). Although there are contradictory data on the impact of thalidomide on stem cell 
mobilization and collection, the effect if any appears to be relatively small with limited impact on the ability 
to proceed with SCT.15,18,33,54 In addition, there is no evidence to suggest that initial therapy with 
thalidomide-containing regimens prior to stem cell collection adversely impacts the engraftment potential 
of the collected stem cells.  
  
Table 1  
 
Studies of novel agents with data available for success of stem cell collection 
In contrast to thalidomide, one of the common adverse effects of lenalidomide has been hematologic 
toxicity, especially myelosuppression. This finding raised concern that use of lenalidomide could adversely 
affect the ability to mobilize and collect adequate numbers of CD34+ cells for ASCT. In 2 large studies from 
Mayo Clinic and M. D. Anderson, the most significant factor influencing the ability to collect adequate 
numbers of stem cells appeared to be initial therapy with lenalidomide (Table 1).33,60 In addition to 
lenalidomide therapy, other important factors impacting the stem cell collection appeared to be the patient 
age and the duration of lenalidomide therapy.33,60 The failure rate of mobilization following lenalidomide 
therapy has varied significantly between the different studies, likely a reflection of the lenalidomide 
treatment duration, age of the patient population undergoing stem cell collection, mobilization regimens, 
and collection targets used. However, data so far do not indicate any impact on the quality of stem cells 
collected, as reflected in the engraftment kinetics as well as success.12,55,56 
The effect of bortezomib on the ability to collect stem cells has also been examined in the context of phase 
2 and 3 trials examining the combinations (Table 1).17,21,49,61 Although no definite impact of initial therapy 
on stem cell harvest was demonstrated in the smaller phase 2 studies of bortezomib and dexamethasone,21 
in the IFM 2005/01 trial comparing bortezomib/dexamethasone to VAD there was a trend toward lower 
CD34 numbers among those receiving bortezomib.17 In contrast, in the HOVON-65/GMMG-HD4 
randomized phase 3 trial comparing bortezomib, adriamycin, dexamethasone (PAD) versus VAD as 
induction treatment, no impact of the regimen was seen on the ability to collect stem cells.62 No significant 
impact of initial therapy has been seen in other trials that have combined the novel agents, bortezomib in 
combination with either lenalidomide or thalidomide.51,63 Addition of alkylating agents to the initial 
therapy, especially in combination, may increase the risk of collection failures, but no comparative data are 
available.48,49 In a phase 2 study looking at the combination of lenalidomide with cytoxan and 
dexamethasone for newly diagnosed myeloma, we observed 8 of 30 failures at mobilization.48 In contrast, 
in a phase 2 study of cytoxan, bortezomib, and dexamethasone by Reeder et al, all patients who attempted 
stem cell collection were able to get enough cells for at least one transplantation.49 
Although there has been a wide spectrum of reported data on the initial therapy with a novel agent and the 
ability to collect stem cells, some common themes have emerged. In the 2 larger experiences published to 
date of lenalidomide therapy prior to harvest, the number of cycles of therapy appears to be important.33,60 
Although none of the patients with fewer than 6 cycles of lenalidomide failed to collect stem cells in the 
Mayo Clinic series, more than 3 cycles of lenalidomide were associated with a higher risk in the M. D. 
Anderson series. However the smaller studies have not demonstrated such a relationship, and in the 
absence of detailed data from the larger prospective studies, it would be reasonable to assume that longer 
duration of therapy will increase the risk of failure. Another common finding has been the age of the 
patients, with more than one study demonstrating increased likelihood of failure in the older patients.33,60 
In these 2 studies, no relationship was noted between the time off lenalidomide prior to stem cell harvest. 
Another important finding across the studies has been the low incidence of collection failure among 
patients mobilized with chemotherapy, typically cyclophosphamide, and G-CSF.58,59 Among 28 treatment-
naive patients treated with the combination of clarithromycin, lenalidomide, and dexamethasone (BiRD) 
reported by Mark et al, sufficient stem cells for 2 autologous stem cell transplantations were collected from 
all patients mobilized with CTX plus G-CSF, versus 33% mobilized with G-CSF alone, demonstrating that this 
approach can potentially overcome the impairment in stem cell mobilization associated with 
lenalidomide.58 For patients failing initial attempts at stem cell mobilization with G-CSF alone, 
chemotherapy + G-CSF approach appears to have a reasonable efficacy. Five of 7 patients failing G-CSF 
alone were successfully mobilized with CTX + G-CSF in one study57 and 18 of 21 patients were remobilized 
successfully with a chemotherapy + G-CSF approach in another study.60 Mazumder et al also reported 3 
patients who failed to collect successfully despite undergoing mobilization with the CXCR4 inhibitor 
plerixafor, but were subsequently collected using a combination of cyclophosphamide and G-CSF.55 
 
Potential mechanisms of the impact of lenalidomide treatment on stem cell collection 
The exact mechanism why lenalidomide inhibits stem cell mobilization is not clear. Koh et al investigated 
the effects of lenalidomide, pomalidomide (CC4047) (IMiDs), and thalidomide on CD34+ hematopoietic 
progenitors. They showed in human colony formation assays and long-term culture-initiating cell tests that 
IMiDs and thalidomide are not toxic to hematopoietic stem cells and do not inhibit self-renewal capacity of 
stem cells.64 This makes it less likely that a direct toxic effect of lenalidomide on hematopoietic progenitors 
explains the limitation in stem cell collection. The group further showed that IMiDs promote myelopoiesis 
with a concomitant maturation stop of neutrophil granulocytes by down-regulation of critical transcription 
factors such as PU.1. This leads to an accumulation of immature granulocytes within the bone marrow 
compartment and neutropenia in the peripheral blood.65 Interestingly, the group also observed that the G-
CSF secretion is highly up-regulated in cultures of hematopoietic progenitors treated with IMiDs (day 3 of 
treatment: control 140 pg/mL, lenalidomide 800 pg/mL, CC4047 1500 pg/mL)64 (S.L., written 
communication, September 2008). The biologic reason for the strong up-regulation of G-CSF is unknown. It 
is likely that self-regulatory mechanisms up-regulate G-CSF to overcome the maturation stop of 
granulocytes. Higher levels of G-CSF might lead to a tachyphylactic response, resulting in resistance to G-
CSF mobilization. These findings are also supported by our observation that all other “non–G-CSF–based” 
mobilization approaches such as CTX and AMD3100 are successful in mobilizing a sufficient CD34+ cell 
number.  
 
Suggested approach to stem cell collection in patients undergoing initial therapy with novel agents 
In June 2008, a panel of experts was convened by the International Myeloma Foundation to address issues 
regarding stem cell collection for autologous transplantation in patients receiving therapy with 
lenalidomide. The following statements reflect the considerations of the panel and the consensus 
recommendations formulated by the panel. The recommendations take into account the existing data 
suggesting compromised collection with the newer agents in some of the patients as well as the data, 
although limited, examining alternate approaches to stem cell mobilization. These recommendations will 
be revised when additional data become available, enabling us to make more specific recommendations.  
First attempt: Given the potential for the novel agents to impact the ability of the stem cell collection, we 
recommend early stem cell mobilization when SCT is being contemplated immediately or later in the course 
of disease. Such an approach, after 3 to 4 cycles of initial therapy, is quite feasible given the rapid response 
seen with the new combinations. However, there exists considerable confusion at this point in terms of the 
mechanisms mediating the decreased collection as well as the best approaches to prevent this problem, 
and every effort should be made to enroll these patients in clinical trials evaluating these questions.  
Among patients undergoing initial therapy with thalidomide or bortezomib in combination with 
dexamethasone or among those treated with lenalidomide and dexamethasone who have received fewer 
than 4 cycles of therapy and are younger than 65 years, G-CSF alone is considered adequate for the initial 
attempt at mobilizing stem cells, although many centers will continue to use cyclophosphamide and G-CSF 
as their standard protocol. Among those who have received more than 4 cycles of lenalidomide therapy, 
one should consider the initial use of cyclophosphamide and G-CSF for mobilization. This suggestion is 
based on the findings of increased failure risk in this population as well as the reduced risk of failure 
associated with the use of cyclophosphamide and G-CSF. Although the use of cyclophosphamide in all 
patients is likely to decrease the risk of failure at first attempt, the recommendation to use G-CSF alone in 
the former group is driven by the low risk of failure in that group, the increased risks and delay associated 
with use of cyclophosphamide, and finally the ability to successfully collect with cyclophosphamide and G-
CSF in the few patients who fail the initial attempt with G-CSF alone. In patients older than 65 years old, we 
recommend consideration of reduced-dose cyclophosphamide with G-CSF or G-CSF alone with addition of 
AMD-3100 before the second leukapheresis if the first leukapheresis results in less than 2 million CD34+ 
cells/kg. In patients receiving other myelosuppressive drugs in combination with lenalidomide, 
cyclophosphamide and G-CSF should be considered for the initial attempt as the rate of failure increases in 
these situations. There are no data supporting additional time off therapy prior to mobilization enhancing 
the likelihood of a successful mobilization. We do not recommend a minimum period that patients have to 
be off lenalidomide prior to starting G-CSF for mobilization.  
Failed stem cell collection 
Among patients receiving initial therapy with lenalidomide-containing regimens failing to collect with G-CSF 
alone, there are 3 options for the subsequent attempt. The majority of the patients can be collected with 
cyclophosphamide priming and G-CSF. These patients will be candidates for use of AMD3100, which in 
combination with G-CSF has been very successful in mobilizing stem cells. Another approach includes the 
use of a combination of G-CSF and granulocyte-macrophage colony-stimulating factor (10 μg/kg per day 
subcutaneously for 2 days, followed by G-CSF 16 μg/kg per day subcutaneously until stem cell collection is 
complete).  
Upfront use of plerixafor (AMD3100) in lenalidomide-treated patients 
The panel discussed the question of routine use of plerixafor for mobilization in this patient group. It was 
felt that at this time, without a detailed cost benefit analysis, such a recommendation cannot be made and 
additional clinical trials specifically addressing its use in these patients will allow us to answer this question. 
Prospective trials should be conducted to study the use of plerixafor in patients failing to reach certain 
thresholds for peripheral blood CD34 counts.  
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